How does retatrutide compare to tirzepatide (Zepbound)?

Both are weekly Eli Lilly subcutaneous injections that hit the GLP-1 and GIP receptors. Retatrutide adds a third receptor arm — glucagon — that drives extra energy expenditure and hepatic-fat mobilization. In Phase 2, retatrutide 12 mg produced roughly 24.2 percent mean weight loss at 48 weeks (Jastreboff 2023 NEJM). Tirzepatide 15 mg produced roughly 20.9 percent at 72 weeks in SURMOUNT-1 (Jastreboff 2022 NEJM). No head-to-head trial exists yet.

How much more weight will people lose on retatrutide vs Zepbound?

Cross-trial comparison suggests roughly 3 to 5 percentage points more mean weight loss on retatrutide at target dose, but this is not a head-to-head comparison. Retatrutide's ~24.2 percent at 48 weeks is a shorter timeframe than tirzepatide's ~20.9 percent at 72 weeks, and Phase 3 TRIUMPH-1 could narrow or widen the gap. Individual response varies substantially — some patients will do better on tirzepatide despite the average difference.

When will retatrutide be FDA-approved?

The earliest realistic FDA approval for the obesity indication is late 2027 to Q2 2028. Eli Lilly has guided the TRIUMPH-1 obesity primary readout for late 2026, with NDA filing likely late 2026 to early 2027. Standard FDA review takes 10 months. Semaglutide moved from STEP-1 readout to Wegovy approval in about 18 months; tirzepatide moved from SURMOUNT-1 to Zepbound in about 19 months. Any Phase 3 safety signal could extend the timeline.

Is retatrutide worth waiting for instead of starting Zepbound?

For most adults with a candidate diagnosis for pharmacotherapy in 2026, no. The realistic wait is 18 to 36 months from now, and untreated obesity accumulates cardiovascular, metabolic, joint, and psychological burden every year. Starting tirzepatide (Zepbound) today is not a lock-in — switching within the same manufacturer's incretin franchise at retatrutide's approval is straightforward. Waiting is only reasonable in narrow cases (modest BMI, prior GLP-1 intolerance) and even then it's a 2-year decision, not a 2-month one.

Are the side effects of retatrutide worse than tirzepatide?

Phase 2 data suggest a higher GI burden — roughly 50 percent nausea and 20 percent vomiting at the 12 mg retatrutide dose vs roughly 25 to 30 percent nausea and 10 percent vomiting at 15 mg tirzepatide. Retatrutide also produced a slightly larger resting heart-rate rise (about 5 to 7 bpm vs 2 to 4 bpm for tirzepatide) attributable to the glucagon arm. Phase 3 uses a more gradual titration than Phase 2, and the discontinuation gap is expected to narrow.

Can I switch from tirzepatide to retatrutide when it's approved?

Yes, and the switch should be straightforward. Both are weekly subcutaneous Eli Lilly injections that share the GLP-1 and GIP receptor pathways, so the mechanism of appetite suppression carries over. Your prescriber will map dose equivalents and likely restart titration on retatrutide to manage the glucagon-arm GI burden. Do not switch on your own. There is no benefit to combining the two drugs, and combining GLP-1 receptor agonists is not standard practice.

Will retatrutide be cheaper than Zepbound?

Probably not at launch. If retatrutide follows the tirzepatide precedent, expect a U.S. list price in the same 1,000 to 1,300 dollars per month range, with a manufacturer direct-to-consumer cash channel (analogous to LillyDirect for Zepbound at 349 to 649 dollars per month) available at a discount. Medicare Part D still excludes anti-obesity drugs by statute, so a cardiovascular indication from TRIUMPH-3 would be the pathway to Medicare coverage — that data reads out 2027 to 2028.

2026-08-22 · retatrutide, tirzepatide, zepbound, mounjaro, GLP-1, GIP, glucagon, triple agonist, TRIUMPH, SURMOUNT, obesity pipeline

Written by Nora Kim

Nora Kim is a WeightFAQ staff writer who translates clinical, surgical, and pharmacological weight-loss research into plain-English guidance. She covers the GLP-1 landscape — semaglutide, tirzepatide, and next-generation drugs — alongside bariatric surgery types, post-op nutrition protocols, and revision options. Her articles also address type 2 diabetes remission, cardiovascular risk, PCOS, fatty liver, night eating syndrome, sarcopenic obesity, and how common medications like antipsychotics, statins, and antidepressants affect weight. Nora writes for readers weighing serious clinical decisions and wanting a clear read on evidence, safety, cost, and realistic outcomes.

11 min read

Medically reviewed on Aug 22, 2026

Two unbranded weekly injector pens angled toward each other on a light matte counter with a stethoscope, small notebook, and glass of water.

How does retatrutide compare to tirzepatide (Zepbound)?: Both are weekly Eli Lilly subcutaneous injections that hit the GLP-1 and GIP receptors. Retatrutide adds a third receptor arm — glucagon — that drives extra energy expenditure and hepatic-fat mobilization. In Phase 2, retatrutide 12 mg produced roughly 24.2 percent mean weight loss at 48 weeks (Jastreboff 2023 NEJM). Tirzepatide 15 mg produced roughly 20.9 percent at 72 weeks in SURMOUNT-1 (Jastreboff 2022 NEJM). No head-to-head trial exists yet.
How much more weight will people lose on retatrutide vs Zepbound?: Cross-trial comparison suggests roughly 3 to 5 percentage points more mean weight loss on retatrutide at target dose, but this is not a head-to-head comparison. Retatrutide's ~24.2 percent at 48 weeks is a shorter timeframe than tirzepatide's ~20.9 percent at 72 weeks, and Phase 3 TRIUMPH-1 could narrow or widen the gap. Individual response varies substantially — some patients will do better on tirzepatide despite the average difference.
When will retatrutide be FDA-approved?: The earliest realistic FDA approval for the obesity indication is late 2027 to Q2 2028. Eli Lilly has guided the TRIUMPH-1 obesity primary readout for late 2026, with NDA filing likely late 2026 to early 2027. Standard FDA review takes 10 months. Semaglutide moved from STEP-1 readout to Wegovy approval in about 18 months; tirzepatide moved from SURMOUNT-1 to Zepbound in about 19 months. Any Phase 3 safety signal could extend the timeline.
Is retatrutide worth waiting for instead of starting Zepbound?: For most adults with a candidate diagnosis for pharmacotherapy in 2026, no. The realistic wait is 18 to 36 months from now, and untreated obesity accumulates cardiovascular, metabolic, joint, and psychological burden every year. Starting tirzepatide (Zepbound) today is not a lock-in — switching within the same manufacturer's incretin franchise at retatrutide's approval is straightforward. Waiting is only reasonable in narrow cases (modest BMI, prior GLP-1 intolerance) and even then it's a 2-year decision, not a 2-month one.
Are the side effects of retatrutide worse than tirzepatide?: Phase 2 data suggest a higher GI burden — roughly 50 percent nausea and 20 percent vomiting at the 12 mg retatrutide dose vs roughly 25 to 30 percent nausea and 10 percent vomiting at 15 mg tirzepatide. Retatrutide also produced a slightly larger resting heart-rate rise (about 5 to 7 bpm vs 2 to 4 bpm for tirzepatide) attributable to the glucagon arm. Phase 3 uses a more gradual titration than Phase 2, and the discontinuation gap is expected to narrow.
Is compounded retatrutide legal or safe?: No, on both counts. Compounding pharmacies cannot legally compound retatrutide under 503A rules because retatrutide has never been on the FDA drug-shortage list — a prerequisite for the compounding pathway. Any product sold as 'compounded retatrutide' or 'research-grade retatrutide' by a telehealth clinic or peptide vendor is unregulated peptide of unverified identity, purity, and dose. It is not the Lilly molecule from the trial, and it is outside every safety-monitoring system that governs approved drugs.
Can I switch from tirzepatide to retatrutide when it's approved?: Yes, and the switch should be straightforward. Both are weekly subcutaneous Eli Lilly injections that share the GLP-1 and GIP receptor pathways, so the mechanism of appetite suppression carries over. Your prescriber will map dose equivalents and likely restart titration on retatrutide to manage the glucagon-arm GI burden. Do not switch on your own. There is no benefit to combining the two drugs, and combining GLP-1 receptor agonists is not standard practice.
Will retatrutide be cheaper than Zepbound?: Probably not at launch. If retatrutide follows the tirzepatide precedent, expect a U.S. list price in the same 1,000 to 1,300 dollars per month range, with a manufacturer direct-to-consumer cash channel (analogous to LillyDirect for Zepbound at 349 to 649 dollars per month) available at a discount. Medicare Part D still excludes anti-obesity drugs by statute, so a cardiovascular indication from TRIUMPH-3 would be the pathway to Medicare coverage — that data reads out 2027 to 2028.

Retatrutide vs Tirzepatide: How Lilly’s Triple Agonist Compares to Zepbound

The one-sentence answer

Retatrutide and tirzepatide are both weekly Eli Lilly injections — tirzepatide is FDA-approved today under the Mounjaro (type 2 diabetes) and Zepbound (obesity + obstructive sleep apnea) labels; retatrutide is the same company’s next-generation triple-agonist candidate that added a glucagon-receptor arm, produced roughly 24 percent weight loss in Phase 2, and is currently in Phase 3 (TRIUMPH program) with earliest realistic FDA availability in 2027 to 2028. If you are choosing today, tirzepatide is on the shelf. If you are tracking what comes next, retatrutide is the direct successor.

At-a-glance	Retatrutide (LY3437943)	Tirzepatide (Mounjaro / Zepbound)
Mechanism	GLP-1 + GIP + glucagon triple agonist	GLP-1 + GIP dual agonist
Regulatory phase	Phase 3 (TRIUMPH program)	FDA-approved (Mounjaro 2022 T2D; Zepbound 2023 obesity; SURMOUNT-OSA 2024)
Peak reported weight loss	~24.2% at 48 wk (Phase 2; Jastreboff 2023 NEJM)	~20.9% at 72 wk (SURMOUNT-1; Jastreboff 2022 NEJM)
Earliest realistic FDA availability	Late 2027 to Q2 2028	On pharmacy shelves today
Current US access	None — not compoundable, not commercially available	Lilly Direct self-pay vials $349–$649/mo; commercial insurance for both labels

Same company, one more receptor

Tirzepatide (LY3298176) is a dual GLP-1 + GIP receptor agonist — one peptide that activates two gut-hormone pathways involved in appetite and glucose control (Frías 2018 NEJM established the SURPASS mechanism). Retatrutide (LY3437943) adds a glucagon receptor arm on top of both. That third leg is the mechanistic novelty (Coskun 2022 Cell Metabolism / Nature Medicine).

The intuitive read on what each receptor does: GLP-1 drives appetite suppression, delayed gastric emptying, and central satiety; GIP adds a complementary appetite-and-insulin signal plus adipose-tissue effects; glucagon — traditionally a fasting glucose-raising hormone — adds two levers the two-receptor and one-receptor drugs do not have, an increase in resting energy expenditure and direct mobilization of hepatic (liver) fat.

That third arm is why retatrutide’s Phase 2 data ran roughly 24.2 percent weight loss at 48 weeks versus tirzepatide’s roughly 20.9 percent at 72 weeks in SURMOUNT-1 — a shorter timeframe at higher magnitude. For the underlying drug pages, see retatrutide for weight loss and tirzepatide for weight loss.

The head-to-head-adjacent trial data

No true head-to-head has been run. The comparison below lines up the two anchor trials — different populations, different durations, different dose-response curves. Cross-trial comparisons always overstate the certainty of the difference.

Retatrutide Phase 2 (Jastreboff 2023 NEJM, n=338, 48 weeks): 12 mg weekly subcutaneous produced roughly −24.2 percent placebo-adjusted mean weight loss at 48 weeks; 100 percent of participants on the top dose lost at least 5 percent of starting weight; 63 percent lost at least 25 percent.
Tirzepatide SURMOUNT-1 (Jastreboff 2022 NEJM, n=2,539, 72 weeks): 15 mg weekly produced roughly −20.9 percent placebo-adjusted at 72 weeks; the 10 mg dose landed at ~19.5% and 5 mg at ~15%.
Tirzepatide SURMOUNT-4 (Aronne 2024 JAMA, n=670, 88 weeks total = 36-week lead-in + 52-week continuation): patients continued on 15 mg maintenance held roughly −25.3 percent total weight loss, while patients switched to placebo regained ~14 percentage points over the 52-week continuation.

The direct efficacy comparison is not yet published because retatrutide Phase 3 TRIUMPH results have not read out. The current tirzepatide-vs-retatrutide magnitude gap is estimated at roughly 3 to 5 percentage points more loss on retatrutide at similar dose intensity, but that number could shrink or grow in Phase 3. For the on-label comparison most patients actually face today — semaglutide against tirzepatide — see semaglutide vs tirzepatide.

Retatrutide Phase 3 TRIUMPH — when do we actually know?

Eli Lilly’s Phase 3 program for retatrutide is organized as the TRIUMPH set covering the major populations retatrutide will eventually be prescribed for. Enrollment began in 2023 and 2024. All primary readouts are pending.

Trial	Population	Primary endpoint	Expected primary readout
TRIUMPH-1	Adults with obesity or overweight + comorbidity, without T2D	Body-weight change at ~76 weeks	Late 2026 (per Lilly guidance)
TRIUMPH-2	Adults with obesity + type 2 diabetes	A1c and weight-loss endpoints	2026 to 2027
TRIUMPH-3	Adults with obesity + established CV disease or CV risk	Major adverse cardiovascular events (MACE)	2027 to 2028
TRIUMPH-4	Adults with obesity + MASH (metabolic dysfunction-associated steatohepatitis)	Liver histology and weight	2027 to 2028

TRIUMPH-1 is the pivotal readout that will anchor an FDA obesity-indication filing. NDA filing is likely late 2026 to early 2027 assuming a clean TRIUMPH-1 readout, with an FDA action target of Q4 2027 to Q2 2028 under standard 10-month review. For the fuller retatrutide-and-pipeline map covering orforglipron, CagriSema, survodutide, MariTide, and mazdutide alongside retatrutide, see next generation weight loss drugs.

The glucagon-arm trade-off — what changes when you add the third receptor

The glucagon arm is what separates retatrutide from tirzepatide, and it cuts both ways.

Benefits of the third receptor arm:

Larger magnitude — the Phase 2 signal is the highest ever reported for an obesity drug at that timeframe.
Hepatic-fat drop — retatrutide Phase 2 MRI-PDFF data showed liver-fat reductions above 80 percent at the top dose, which is why TRIUMPH-4 in MASH is a priority indication.
Lipid signal — LDL was modestly down and triglycerides dropped roughly 30 percent at the top dose.
Higher resting energy expenditure — the glucagon arm adds an energy-out lever the two-receptor drugs do not have.

Trade-offs of the third receptor arm:

Resting heart rate rises about 5 to 7 bpm at target dose — a glucagon-class signal, larger than tirzepatide’s 2 to 4 bpm rise.
Higher nausea and vomiting — roughly 50 percent nausea at 12 mg retatrutide vs roughly 25 to 30 percent at 15 mg tirzepatide.
Transient liver-enzyme rises more common — Phase 2 did not show a hepatic safety signal, but Phase 3 in a larger population is the definitive read.

Retatrutide is being trialed in MASH (TRIUMPH-4) precisely because the glucagon arm mobilizes liver fat, but the same mechanism is why the safety-monitoring bar in Phase 3 is higher.

Side-effect comparison

The GI-tolerance and discontinuation numbers below anchor to the SURMOUNT-1 tirzepatide 15 mg arm and the retatrutide 12 mg arm of the Jastreboff 2023 Phase 2 trial. Retatrutide’s Phase 3 program uses a more gradual titration than Phase 2 did — the discontinuation gap is expected to narrow at approval.

Side effect at target dose	Tirzepatide 15 mg (SURMOUNT-1)	Retatrutide 12 mg (Phase 2)
Nausea	25–30%	~50%
Vomiting	~10%	~20%
Diarrhea	~15%	~25%
Constipation	~10%	~15%
Treatment discontinuation	~5%	~10%

For the class-wide safety picture that applies to every GLP-1 (boxed warning for medullary thyroid cancer risk, pancreatitis, gallbladder events, hypoglycemia risk with insulin or sulfonylureas), see Ozempic side effects and weight loss drug safety. Because both drugs deliver high-magnitude weight loss, the muscle-preservation and lean-mass concerns that apply to any deep deficit apply here too — see preserve muscle during weight loss for the protein and resistance-training scaffolding that offsets it.

Cost and access — the huge gap

The pricing story in 2026 is not a comparison. It is a gap between an on-shelf option and a drug you cannot legally buy at any price.

Tirzepatide today:

U.S. list price roughly $1,060 per month for Zepbound
Lilly Direct self-pay vials at approximately $349–$649 per month depending on dose
Commercial insurance coverage for both Mounjaro (T2D) and Zepbound (obesity + OSA) under prior authorization
Manufacturer savings card for eligible commercially insured patients

Retatrutide today:

Not FDA-approved. No US commercial availability. No legal compounding pathway.
Small ClinicalTrials.gov TRIUMPH sites still enrolling in some markets

Retatrutide when approved (2027 to 2028 estimate):

Expected list price in the same $1,000 to $1,300 per month range as tirzepatide, based on class pricing
A Lilly Direct-style cash channel is likely, at a discount
Medicare Part D anti-obesity-drug exclusion still applies under current 2026 federal rules unless amended; TRIUMPH-3 cardiovascular data is the pathway to a Medicare route (following Wegovy under SELECT and Zepbound under SURMOUNT-OSA)

For the full 2026 pricing landscape across the class, savings card mechanics, and Medicare pathways, see GLP-1 cost and insurance and the prescription weight loss medications hub.

Should you wait for retatrutide?

The honest answer for most adults with a candidate diagnosis for pharmacotherapy in 2026 is no, don’t wait.

You should not wait if:

Your BMI or comorbidity burden means starting today produces meaningful health benefit within the next two years — weight-related sleep apnea, uncontrolled type 2 diabetes, cardiovascular risk, physical function decline. Start tirzepatide (or semaglutide) now, plan to reassess after retatrutide approval.
You have already been titrated on a GLP-1 and are tolerating it. Waiting means giving up months of progress for a drug that is not yet on the shelf.
You are relying on employer commercial insurance that currently covers Zepbound. Coverage decisions can change year to year; a plan that covers tirzepatide today may not cover retatrutide the day it launches.

Waiting may be reasonable if:

You have modest BMI (27–30), tolerated GLP-1s poorly in a previous course, and are specifically looking for a MASH-and-obesity combined therapy.
You are enrolled in a TRIUMPH trial site.

Even in those cases, waiting is a 2-year decision, not a 2-month one. Switching from tirzepatide to retatrutide at approval will be straightforward — the same-manufacturer, same-titration format, and shared GLP-1 + GIP mechanism make a within-class switch simple.

The compounded-retatrutide reality in 2026

This is the section that matters most for reader safety.

There is no legal compounded retatrutide in the United States under 503A pharmacy compounding rules. The 503A/503B compounding pathway requires either an FDA drug-shortage listing (which briefly covered compounded semaglutide and tirzepatide in 2022 to 2024 during genuine shortage) or an approved active ingredient. Retatrutide has never been on the shortage list — it has never been approved — so the legal basis for compounding it does not exist.

Products sold as “compounded retatrutide” or “research-grade retatrutide” by a telehealth vendor, gray-market compounding pharmacy, or research-peptide website are unregulated peptides of unverified identity. Rubino 2023 (JAMA) analyzed compounded semaglutide samples during the 2023 shortage window and documented mislabeled potency, subpotent product, wrong salt forms, and bacterial contamination. Retatrutide compounding, fully outside any legal pathway, has even less oversight. What arrives in the vial may contain no active drug, the wrong dose, or an entirely different molecule.

For the full 2026 compounded-injectable-safety framework, see compounded semaglutide and tirzepatide safety. The correct answer for a reader who wants retatrutide is to wait for the FDA-approved product.

Practical bottom line

If you and a prescriber decide GLP-1-based therapy is right for you in 2026, tirzepatide is the on-shelf option — Zepbound for obesity or OSA, Mounjaro for type 2 diabetes. Retatrutide will not be a legitimate US option until 2027 to 2028 at the earliest.

The Phase 2 magnitude advantage is real (roughly 3 to 5 percentage points more mean weight loss), and the added glucagon-receptor arm drives the hepatic-fat and lipid signal, at the cost of a higher GI-adverse-event rate and a larger resting heart-rate rise. When retatrutide arrives, switching within the same manufacturer’s incretin franchise is simple — do not delay a today decision for a 2-year drug. For the four-way brand-by-brand map across every currently approved GLP-1, see GLP-1 medications compared.

Sources

Nora Kim

Medical weight loss writer

Nora Kim covers medical and surgical weight loss options, GLP-1 therapies, and evidence-based supplements. She focuses on explaining clinical research, safety considerations, and practical next steps so readers can discuss treatment choices with their care teams.